Sangamo Therapeutics Inc Cash Flow Conversion Efficiency
Sangamo Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Sangamo Therapeutics Inc (SGMO) has a cash flow conversion efficiency ratio of -4.565x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.50 Million) by net assets ($6.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Sangamo Therapeutics Inc (1999–2024)
Cash flow conversion efficiency of Sangamo Therapeutics Inc from 1999 to 2024. This chart illustrates how Sangamo Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Sangamo Therapeutics Inc (SGMO) share price today for real-time trading data and today's change.
Sangamo Therapeutics Inc Cash Flow Conversion Ratio Explained
Sangamo Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sangamo Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sangamo Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Sangamo Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shinwha Intertek Corp
KQ:056700
|
0.011x |
|
Bowen Acquisition Corp Ordinary Shares
NASDAQ:BOWN
|
0.000x |
|
Scienjoy Holding Corp
NASDAQ:SJ
|
0.008x |
|
M.K. Real Estate Development Public Company Limited
BK:MK
|
0.037x |
|
Advance Zinctek Ltd
AU:ANO
|
0.024x |
|
BranchOut Food Inc. Common Stock
NASDAQ:BOF
|
-0.624x |
|
SEKONIX Co. Ltd
KQ:053450
|
-0.010x |
|
NH Special Purpose Acquisition 21 Co. Ltd.
KQ:391710
|
0.166x |
Annual Cash Flow Conversion Efficiency for Sangamo Therapeutics Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Sangamo Therapeutics Inc from 1999 to 2024. Review cash generation quality of Sangamo Therapeutics Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $22.77 Million | $-67.14 Million | -2.949x | -8.70% |
| 2023-12-31 | $82.89 Million | $-224.84 Million | -2.713x | -257.79% |
| 2022-12-31 | $294.96 Million | $-223.63 Million | -0.758x | -22.00% |
| 2021-12-31 | $375.34 Million | $-233.25 Million | -0.621x | -281.95% |
| 2020-12-31 | $497.37 Million | $169.88 Million | 0.342x | +202.35% |
| 2019-12-31 | $432.74 Million | $-144.40 Million | -0.334x | -429.20% |
| 2018-12-31 | $366.52 Million | $37.15 Million | 0.101x | +70.38% |
| 2017-12-31 | $187.90 Million | $11.18 Million | 0.059x | +112.30% |
| 2016-12-31 | $136.19 Million | $-65.88 Million | -0.484x | -176.07% |
| 2015-12-31 | $192.44 Million | $-33.72 Million | -0.175x | -538.01% |
| 2014-12-31 | $206.63 Million | $-5.67 Million | -0.027x | +82.84% |
| 2013-12-31 | $121.71 Million | $-19.48 Million | -0.160x | -28.53% |
| 2012-12-31 | $64.90 Million | $-8.08 Million | -0.125x | +61.46% |
| 2011-12-31 | $80.13 Million | $-25.89 Million | -0.323x | +24.51% |
| 2010-12-31 | $55.91 Million | $-23.93 Million | -0.428x | -400.74% |
| 2009-12-31 | $71.78 Million | $-6.14 Million | -0.085x | +72.69% |
| 2008-12-31 | $55.40 Million | $-17.34 Million | -0.313x | -40.54% |
| 2007-12-31 | $72.12 Million | $-16.07 Million | -0.223x | +25.05% |
| 2006-12-31 | $48.70 Million | $-14.48 Million | -0.297x | -176.25% |
| 2005-12-31 | $37.81 Million | $-4.07 Million | -0.108x | +65.72% |
| 2004-12-31 | $32.38 Million | $-10.16 Million | -0.314x | -88.44% |
| 2003-12-31 | $44.66 Million | $-7.44 Million | -0.167x | +6.57% |
| 2002-12-31 | $54.25 Million | $-9.67 Million | -0.178x | -140.42% |
| 2001-12-31 | $82.35 Million | $-6.11 Million | -0.074x | -102.14% |
| 2000-12-31 | $66.89 Million | $-2.45 Million | -0.037x | +87.92% |
| 1999-12-31 | $7.90 Million | $-2.40 Million | -0.304x | -- |
About Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a ch… Read more